CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure Glucose-lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People With or at Risk of Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome Trials Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Trials Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification Nitrosative stress drives heart failure with preserved ejection fraction

Original Research

JOURNAL:CBSMD Article Link

Atrial Fibrillation and the Risk of Heart Failure

CBSMD

Pre-reading

Atrial Fibrillation and the Risk of Heart Failure


June, 2018 "Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure" pointed out patients with a pacemaker or defibrillator, short-lasting, subclinical atrial fibrillation (SCAF) progression was strongly associated with HF hospitalization.



In a nationally representative cohort, US National Readmissions Database, which collects data from 22 states. There were 60,203 adults who underwent CA of AF. The primary endpoint was early mortality, defined as mortality either during the index ablation hospitalization or during 30-day rehospitalizations. Early mortality following AF ablation affected nearly 1 in 200 patients, with the majority of deaths occurring during 30-day readmission. Procedural complications, congestive heart failure, and low hospital AF ablation volume were predictors of early mortality. Prompt management of post-procedure complications and CHF may be critical for reducing mortality rates following AF ablation. The mortality rate reported in this study is likely to be an underestimate, because deaths that occurred outside the hospital or in a state other than the one in which the index ablation procedure was performed were not accounted for in the National Readmissions Database. In addition to early identification and treatment of a complication and HF, the data suggest that mortality also could be improved by restricting low-volume hospitals from performing AF CA procedures in the absence of an experienced proctor.


1. Screening for Atrial Fibrillation With ECG: USPSTF Recommendation

2. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society